Fluticasone: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), HAS (France) and PHARMAC (New Zealand), among others, recommended or restricted fluticasone, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 17.2 years separate the first record, 19 Mar 2008 at HAS (France), from the most recent, 14 May 2025 at HAS (France).
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for fluticasone, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 6 of 31 records date from 2023 or later.
4 distinct indication wordings are recorded for fluticasone by the agencies that label one in English (AWMSG, PBAC and SMC).
9 of these 31 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess fluticasone, on 19 Mar 2008; CIPM (Spain) did not open a file until 26 Sep 2024 — an unusually long tail of 16.5 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 14 years in total.
4 of the 8 agencies here assessed fluticasone more than once, HAS (France) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for fluticasone.
The full ledger for fluticasone reads 19 recommended, 5 other, 5 not recommended and 1 withdrawn, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 14 May 2025 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| CIPM (Spain) | 26 Sep 2024 | Indicación terapéutica autorizada: Furocort está indicado en adultos, adolescentes y niños (6 años y mayores). Furocort … | financed by the SNS · art. 92 d, e | source |
| PHARMAC (New Zealand) | 20 Mar 2023 | Asthma | PTAC advice: No Formal Recommendation | source |
| PBAC (Australia) | 2021 | Asthma | Recommendation was rescinded by the PBAC, noting that there were two alternate strengths o… | source |
| CONITEC (Brazil) | 30 Sep 2015 | Redução dos sintomas e exacerbações da asma em pacientes tratados com broncodilatadores isolados ou outra terapia profil… | not incorporated | source |
26 further decisions for fluticasone, across 7 agencies, are not shown here. They link to 14 further source documents.
Related molecules
- azelastine / fluticasone — same ATC class R01A — Nasal preparations
- fluticasone / formoterol — same ATC class R01A — Nasal preparations
- ciclesonide — same ATC class R01A — Nasal preparations
- mometasone — same ATC class R01A — Nasal preparations
- fluticasone / umeclidinium / vilanterol — same ATC class R01A — Nasal preparations
- azelastine — same ATC class R01A — Nasal preparations
Coverage: 31 decisions for fluticasone from 8 agencies, 2008 to 2025. Data to 7 Sep 2026. ATC class R01A — Nasal preparations. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.